- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring the Placebo Response in Cancer Survivors
A clinical trial at the University of Alabama will be enrolling patients in the first-ever study of an open-label placebo in cancer.
A clinical trial at the University of Alabama will be enrolling patients in the first study of an open-label placebo in cancer. Cancer survivors with moderate-levels of cancer-related fatigue, who have completed treatments for at least 6 months, would be eligible to participate.
One group of participants will receive the placebo pill for 2 weeks and the second group will act as a control. The cohorts will trade places after a week-long washout period. Saliva samples from trial participants will be analyzed for potential biomarkers to identify genetic predisposition to a placebo response, if any.
The Program in Placebo Studies and the Therapeutic Encounter at Harvard University and Beth Israel Deaconess Medical Center, run by Ted Kaptchuk, has done several open-label placebo studies in patients with irritable bowel syndrome, migraine, and depression.
Read more at newswise: http://bit.ly/1Lo2wZ4
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
